Status:
COMPLETED
Dose Ranging Study To Assess Efficacy, Safety and Tolerability Of PF-06700841 Topical Cream In Psoriasis
Lead Sponsor:
Pfizer
Conditions:
Psoriasis
Eligibility:
All Genders
18-75 years
Phase:
PHASE2
Brief Summary
This is a Phase 2b, randomized, double blind, vehicle controlled, parallel group, multicenter study in participants with mild to moderate plaque psoriasis. The duration of study participation will be ...
Eligibility Criteria
Inclusion
- plaque psoriasis for 6 months
- PGA score mild or moderate
- body surface area (BSA) 2-15%
Exclusion
- other skin conditions that would interfere with the evaluation of psoriasis
- history of herpes zoster or simplex
- Infected with Mycobacterium tuberculosis
Key Trial Info
Start Date :
April 8 2019
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 20 2021
Estimated Enrollment :
344 Patients enrolled
Trial Details
Trial ID
NCT03850483
Start Date
April 8 2019
End Date
April 20 2021
Last Update
June 29 2022
Active Locations (79)
Enter a location and click search to find clinical trials sorted by distance.
1
Center for Dermatology and Plastic Surgery/CCT
Scottsdale, Arizona, United States, 85260
2
Center for Dermatology and Plastic Surgery
Scottsdale, Arizona, United States, 85260
3
Burke Pharmaceutical Research
Hot Springs, Arkansas, United States, 71913
4
Anaheim Clinical Trials, LLC
Anaheim, California, United States, 92801